Antibody cocktails for breast cancer radioimmunotherapy
AssigneeRutgers, The State University of New Jersey
InventorsRoger W. Howell, John M. Akudugu, Jordan B. Pasternack
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions comprising a therapeutically effective combination of at least two of radionuclide-labeled anti-Epidermal Growth Factor Receptor (anti-EGFR), radionuclide-labeled anti-CD-44, and radionuclide-labeled anti-CD-73. or their respective antigen binding portions, and a pharmaceutically acceptable carrier, and method of use thereof for the treatment of breast cancer.
Claims16
A composition comprising at least two of radionuclide-labeled anti-Epidermal Growth Factor Receptor (anti-EGFR) or an antigen binding portion thereof, radionuclide-labeled anti-CD-44 or an antigen binding portion thereof, and radionuclide-labeled anti-CD-73 or an antigen binding portion thereof, and a pharmaceutically acceptable carrier.
The method of treating breast cancer in a subject comprising the steps of identifying a subject in need of such treatment, and administering to the subject a composition comprising a therapeutically effective combination of at least two of radionuclide-labeled anti-Epidermal Growth Factor Receptor (anti-EGFR) or an antigen binding portion thereof, radionuclide-labeled anti-CD-44 or an antigen binding portion thereof, and radionuclide-labeled anti-CD-73 or an antigen binding portion thereof, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.